VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP
- PMID: 25503977
- PMCID: PMC4745134
- DOI: 10.1160/TH14-09-0731
VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP
Abstract
Absent or severely diminished activity of ADAMTS13 (A Disintegrin And Metalloprotease with a ThromboSpondin type 1 motif, member 13) resulting in the intravascular persistence and accumulation of highly thrombogenic ultra large von Willebrand factor (UL-VWF) multimers is the pathophysiological mechanism underlying thrombotic thrombocytopenic purpura. Reduced VWF-cleaving protease levels, however, are not uniquely restricted to primary thrombotic microangiopathy (TMA), e. g. thrombotic thrombocytopenic purpura, but also occur in other life-threatening thrombocytopenic conditions: severely decreased ADAMTS13 activity is seen in severe sepsis, disseminated intravascular coagulation (DIC) and complicated malarial infection. The clinical relevance of these secondary thrombotic microangiopathies is increasingly recognised, but its therapeutic implications have not yet been determined. The presence of a secondary TMA in certain diseases may define patient groups which possibly could benefit from ADAMTS13 replacement or a VWF-targeting therapy. This short-review focuses on the role of UL-VWF multimers in secondary TMA and discusses the potential of investigational therapies as candidates for the treatment of TTP. In conclusion, prospective clinical trials on the effectiveness of protease replacementin vivo seem reasonable. Carefully selected patients with secondary TMA may benefit from therapies primarily intended for the use in patients with TTP.
Keywords: ADAMTS13; DIC; TTP; VWF; malaria; sepsis.
Figures

Similar articles
-
Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases.Semin Thromb Hemost. 2007 Nov;33(8):787-97. doi: 10.1055/s-2007-1000365. Semin Thromb Hemost. 2007. PMID: 18175284 Review.
-
[Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].Rinsho Byori. 2015 Oct;63(10):1228-36. Rinsho Byori. 2015. PMID: 26897861 Review. Japanese.
-
Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13.Semin Thromb Hemost. 2012 Feb;38(1):47-54. doi: 10.1055/s-0031-1300951. Epub 2012 Feb 7. Semin Thromb Hemost. 2012. PMID: 22314603 Review.
-
Thrombotic thrombocytopenic purpura and anti-thrombotic therapy targeted to von Willebrand factor.Curr Vasc Pharmacol. 2012 Nov;10(6):762-6. doi: 10.2174/157016112803520837. Curr Vasc Pharmacol. 2012. PMID: 22022775 Review.
-
Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases.Thromb Res. 2012 May;129(5):598-602. doi: 10.1016/j.thromres.2011.10.011. Epub 2011 Nov 8. Thromb Res. 2012. PMID: 22070827
Cited by
-
Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients.TH Open. 2021 Mar 9;5(1):e89-e103. doi: 10.1055/s-0041-1723784. eCollection 2021 Jan. TH Open. 2021. PMID: 33709050 Free PMC article.
-
Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy-Either, Neither, or Both.Semin Thromb Hemost. 2020 Oct;46(7):781-784. doi: 10.1055/s-0040-1712156. Epub 2020 Jun 8. Semin Thromb Hemost. 2020. PMID: 32512589 Free PMC article. Review. No abstract available.
-
The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study.Ann Transl Med. 2022 Sep;10(18):975. doi: 10.21037/atm-22-3814. Ann Transl Med. 2022. PMID: 36267762 Free PMC article.
-
Research Advances in the Subtype of Sepsis-Associated Thrombocytopenia.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620959467. doi: 10.1177/1076029620959467. Clin Appl Thromb Hemost. 2020. PMID: 33054353 Free PMC article.
-
Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.WIREs Mech Dis. 2022 Nov;14(6):e1576. doi: 10.1002/wsbm.1576. Epub 2022 Jul 24. WIREs Mech Dis. 2022. PMID: 35871757 Free PMC article. Review.
References
-
- Ruggeri ZM, Ware J. von Willebrand factor. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 1993;7(2):308–16. - PubMed
-
- Lenting PJ, Casari C, Christophe OD, et al. von Willebrand factor: the old, the new and the unknown. Journal of thrombosis and haemostasis : JTH. 2012;10(12):2428–37. - PubMed
-
- Vischer UM, Barth H, Wollheim CB. Regulated von Willebrand factor secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells. Arteriosclerosis, thrombosis, and vascular biology. 2000;20(3):883–91. - PubMed
-
- Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104(1):100–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous